Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.37 CHF | +0.82% | +0.75% | +2.95% |
Mar. 28 | NOVARTIS AG : Barclays gives a Sell rating | ZD |
Mar. 25 | NOVARTIS AG : Berenberg remains Neutral | ZD |
Sales 2024 * | 48.14B 43.39B | Sales 2025 * | 50.19B 45.24B | Capitalization | 212B 191B |
---|---|---|---|---|---|
Net income 2024 * | 10.05B 9.06B | Net income 2025 * | 11.03B 9.95B | EV / Sales 2024 * | 4.65 x |
Net Debt 2024 * | 11.49B 10.36B | Net Debt 2025 * | 10.14B 9.14B | EV / Sales 2025 * | 4.43 x |
P/E ratio 2024 * |
18.9
x | P/E ratio 2025 * |
16.7
x | Employees | 76,057 |
Yield 2024 * |
3.85% | Yield 2025 * |
3.97% | Free-Float | 81.95% |
Latest transcript on Novartis AG
1 day | +0.82% | ||
1 week | +2.66% | ||
Current month | -2.37% | ||
1 month | -3.62% | ||
3 months | +3.76% | ||
6 months | -5.51% | ||
Current year | +2.95% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +7.01% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 87.37 | +0.82% | 2,973,660 |
24-03-27 | 86.66 | +0.59% | 2,823,832 |
24-03-26 | 86.15 | -0.30% | 2,390,891 |
24-03-25 | 86.41 | -0.12% | 1,801,019 |
24-03-22 | 86.51 | -0.24% | 2,157,126 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.95% | 210B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
-6.05% | 201B | |
-3.61% | 157B | |
-1.28% | 153B |